Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accumulated Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Accumulated Expenses for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 6.36% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 6.36% year-over-year, with the annual reading at $1.3 million for FY2025, 6.36% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $1.3 million at bioAffinity Technologies, up from $984547.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $1.6 million in Q3 2022, with the low at $276519.0 in Q2 2023.
  • Average Accumulated Expenses over 4 years is $848667.4, with a median of $762887.0 recorded in 2024.
  • The sharpest move saw Accumulated Expenses crashed 59.76% in 2023, then soared 171.12% in 2024.
  • Over 4 years, Accumulated Expenses stood at $541894.0 in 2022, then surged by 58.16% to $857037.0 in 2023, then soared by 63.2% to $1.4 million in 2024, then dropped by 6.36% to $1.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.3 million, $984547.0, and $776065.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.